后房型有晶状体眼人工晶状体矫治高度近视眼的3年随访报告

目的 观察后房型有晶状体眼人工晶状体(PCPIOL)矫治高度近视眼的长期安全性和有效性.方法 高度近视眼患者41例(66只眼),等效球镜度数(SE)(-15.12±3.93)D,植入PCPIOL.术后随访3年,观察手术前后的视力、屈光状态、眼压、角膜、前房、瞳孔、PCPIOL和晶状体、眼底情况,并进行比较.结果 与术前比较,术后3、6个月、1、2、3年的裸眼视力(UCVA)、最佳矫正视力(BCVA)和SE显著改善.术后3年时,UCVA≥0.5有86%,≥0.8有43%;BCVA未见下降,11%比术前提高1行,68%比术前提高≥2行;96%眼的实际屈光度数稳定在预期的±1.00D,57%稳定在预期的±0.50D.术后1、2、3年的角膜内皮细胞累积丢失率分别为9.26%、12.84%、18.54%.除了1只眼黄斑出血外,未见其他并发症发生.结论 PCPIOL矫治高度近视术后3年内安全、有效.

Three-year follow-up of posterior chamber phakic intraocular lens implantation for high myopia

Objective To investigate long-term efficacy and safety ofa posterior chamber phakic intraocular lens (PCPIOL) implantation for high myopia. Methods A consecutive group of 66 eyes in 41 patients with -15.12± 3.93 diopters (D) of myopia was implanted with the ICL PCPIOL (STAAR), and was examined preoperatively and 1, 2, 3 years postoperatively. Uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), manifest refraction, intraocular pressure, and complications were evaluated. Results The implantation was successful in all of 66 eyes. Compared with preoperative data, UCVA, BCVA, and spherical equivalent (SE) were improved significantly. At 3-year postoperatively, UCVA in 86% eyes was 0.5 or better, in 43% was 0.8 or better; No loss of BCVA was found, 11% gained 1 line, and 68% gained 2 lines or more; SE in 96%, 57% eyes was within ± 1.00 D, ± 0.50D of attempted, respectively. At 1-, 2-, 3-year follow-up, the corneal endothelial loss was 9.26%, 12.84%, 18.54%, respectively. No severe complications occurred expect 1macular hemorrhage due to CNV. Conclusions At 3-year follow-up, the implantation of the PCPIOL proved to be safe and effective for the correction of myopia in phakic eyes.